UltiMaker Printers Are Mass-Producing 3D-Printed Synthetic Skin in a Singapore Cleanroom

UltiMaker has signed a Memorandum of Understanding with Singapore-based startup Bioactivx to scale up the production of a 3D-printed synthetic skin substitute for burn treatment. The announcement coincides with the opening of Bioactivx's medical-grade filament production facility and cleanroom print farm, and with the product earning Singapore Health Sciences Authority approval.

The product, called Bioactiv Matrix, is a fully synthetic, animal-free regenerative wound-care material. It is designed to accelerate wound closure and promote scar-free healing. The material requires no special storage, which removes a major logistical hurdle for burn wards outside major hospital systems.

Bioactivx built its entire manufacturing process around UltiMaker's desktop-style FFF printers. The company compounds its own proprietary active-ingredient filament in-house, then prints finished product on a fleet of UltiMaker machines inside an ISO 13485-certified cleanroom. That certification is the same quality-management standard used for surgical implants and diagnostic hardware, not a general manufacturing checkbox.

Dr Teo Peili, CEO of Bioactivx, explained the hardware choice directly: the team picked UltiMaker for reliability, ease of use, and open architecture. That openness let them develop their own proprietary print process without being locked into a closed ecosystem. The statement is a practical argument for open-hardware platforms in medical manufacturing.

Why this matters for 3D printing

Most stories about desktop FFF printers in production involve jigs, fixtures, or short runs of plastic brackets. Bioactivx has taken the platform considerably further: certified cleanroom production of an end-use medical device with regulatory approval. ISO 13485 certification and HSA clearance mean the process, not just the product, meets rigorous medical standards.

Regulatory submissions for the Bioactiv Matrix are now underway in the United States, European Union, Australia, and across ASEAN. If the product clears FDA or EU pathways, it will reach a considerably higher bar than the HSA approval already secured. The MOU with UltiMaker focuses on co-developing a scalable, on-demand printing solution that brings wound-care production closer to the point of need, reducing reliance on cold-chain logistics and centralized manufacturing.

The collaboration is also a proof point for the broader medical 3D-printing industry. It shows that non-industrial, open-architecture hardware can meet end-use medical device standards when the surrounding material science, quality control, and facility certification are rigorous enough. That is a meaningful data point for anyone assuming medical-grade additive manufacturing requires proprietary systems costing hundreds of thousands of dollars.